TGFB3 and prostate cancer: Finally, we selected TGFB3 for further analysis since it repositioned in one of two low risk Gleason score 6 prostate cancers, but not in two prostate cancers of unknown Gleason score and TNM stage (Meaburn et al., 2016), representing a potential low-risk/indolent prostate cancer biomarker.